We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Solvatochromic Trehalose Probe Rapidly Detects TB

By LabMedica International staff writers
Posted on 13 Mar 2018
Print article
Image: A new technique that makes tuberculosis bacteria glow detects living Mycobacterium tuberculosis cells that have not been treated with drugs (left) but not those that have been treated (right) (Photo courtesy of Stanford University).
Image: A new technique that makes tuberculosis bacteria glow detects living Mycobacterium tuberculosis cells that have not been treated with drugs (left) but not those that have been treated (right) (Photo courtesy of Stanford University).
Despite its devastating toll on health, the bacteria causing tuberculosis (TB), Mycobacterium tuberculosis, can be hard to spot. Current tests rely on chemical stains and estimates put the sensitivity of these stains anywhere from 32% to 94%.

Better detection methods are sorely needed to combat TB, which killed more than 1.7 million people worldwide in 2016. A new staining technique has been developed that is quick and simple and detects the pernicious bacteria that are a major cause of deadly lung infection that is particularly common in developing countries.

A team of international scientists led by those at Stanford University (Stanford, CA, USA) designed a color-changing dye based on trehalose, a sugar that makes up the outer membrane of M. tuberculosis. The dye stained live bacteria within minutes, emitting fluorescence upon incorporation into the hydrophobic mycobacterial membrane. Heat-inactivated bacteria did not fluoresce, and drug-treated bacteria emitted reduced fluorescence.

The designed 4-N,N-dimethylamino-1,8-naphthalimide–conjugated trehalose (DMN-Tre) probe undergoes >700-fold increase in fluorescence intensity when transitioned from aqueous to hydrophobic environments. This enhancement occurs upon metabolic conversion of DMN-Tre to trehalose monomycolate and incorporation into the mycomembrane of Actinobacteria. DMN-Tre labeling enabled the rapid, no-wash visualization of mycobacterial and corynebacterial species without nonspecific labeling of Gram-positive or Gram-negative bacteria. Microscopy was performed on a Nikon A1R confocal microscope equipped with a Plan Fluor 60× oil immersion 1.30–numerical aperture objective.

In tests on sputum samples from 16 people with TB, DMN-Tre picked up M. tuberculosis cells in all of the samples. The new technique performed similarly to the standard, but more complex and time-consuming, labeling method based on the Auramine O stain, a dye that sticks to acids in bacterial cell walls. Human cells and other types of bacteria, both of which are plentiful in sputum samples, do not incorporate the molecule.

Unlike existing TB detection methods, DMN-Tre can also distinguish cells that are metabolically active from those that are not. Because the molecule relies on bacteria to actively incorporate it into the membrane, only healthy cells are labeled, whereas cells that are compromised by drug treatment do not label as well. That property may allow clinicians to monitor how well treatments are working in people, and perhaps even test whether certain mixtures of drugs would work against specific strains of M. tuberculosis. The study was published on February 28, 2018, in the journal Science Translational Medicine.

Related Links:
Stanford University

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.